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Tonic conductance mediated by extrasynaptic GABAA receptors has been implicated in the modulation of
network oscillatory activity. Using an in vitro brain slice to produce oscillatory activity and a kinetic
model of GABAA receptor dynamics, we show that changes in tonic inhibitory input to fast spiking in-
terneurons underlie benzodiazepine-site mediated modulation of neuronal network synchrony in rat
primary motor cortex. We found that low concentrations (10 nM) of the benzodiazepine site agonist,
zolpidem, reduced the power of pharmacologically-induced beta-frequency (15e30 Hz) oscillatory ac-
tivity. By contrast, higher doses augmented beta power. Application of the antagonist, ﬂumazenil, also
increased beta power suggesting endogenous modulation of the benzodiazepine binding site.
Voltage-clamp experiments revealed that pharmacologically-induced rhythmic inhibitory postsynaptic
currents were reduced by 10 nM zolpidem, suggesting an action on inhibitory interneurons. Further
voltage-clamp studies of fast spiking cells showed that 10 nM zolpidem augmented a tonic inhibitory
GABAA receptor mediated current in fast spiking cells whilst higher concentrations of zolpidem reduced
the tonic current. A kinetic model of zolpidem-sensitive GABAA receptors suggested that incubation with
10 nM zolpidem resulted in a high proportion of GABAA receptors locked in a kinetically slow desensi-
tized state whilst 30 nM zolpidem favoured rapid transition into and out of desensitized states. This was
conﬁrmed experimentally using a challenge with saturating concentrations of GABA. Selective modu-
lation of an interneuron-speciﬁc tonic current may underlie the reversal of cognitive and motor deﬁcits
afforded by low-dose zolpidem in neuropathological states.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The primary motor cortex (M1) exhibits neuronal network
oscillatory activity at beta frequency (15e30 Hz) (Murthy and Fetz,artiﬁcial cerebrospinal ﬂuid;
current; M1, primary motor
synaptic currents; KA, kainic
otential; ODEs, ordinary dif-
(G. Ladds), G.L.Woodhall@
r Ltd. This is an open access articl1992; Baker et al., 1997). The power of this oscillatory activity is
dynamic, changingwith the anticipation, initiation and termination
of movement (Cheyne et al., 2008). Loss of dynamicity through
excessive synchronization and raised oscillatory power may un-
derlie deﬁcits associated with Parkinson's disease (Brown, 2003;
Brown et al., 2004; Kuhn et al., 2006). Similarly, other neuropa-
thologies involve altered oscillatory activity, including stroke
(Tecchio et al., 2006; Hall et al., 2010), Alzheimer's disease (Poza
et al., 2007) and schizophrenia (Canive et al.,1996; Ford et al., 2007).
As with gamma (35e80 Hz) oscillations (Whittington et al.,
1995; Traub et al., 1996), beta oscillatory activity in M1 is gener-
ated as a consequence of sustained excitation of networks of
inhibitory interneurons (Yamawaki et al., 2008). Inhibitory in-
terneurons are able to entrain each other to ﬁre in a synchronous
manner and hence sculpt pyramidal cell activity through repetitive
(phasic) inhibitory discharges, the frequency of which is dependente under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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(Whittington et al., 1995; Fisahn et al., 1998; Traub et al., 2003).
Recent evidence suggests that a sustained inhibitory membrane
conductance (Itonic), arising from spillover of GABA, and mediated
by high afﬁnity extrasynaptic GABAA receptors (Farrant and Nusser,
2005; Bright et al., 2007) also plays a fundamental role in shaping
network excitability (Semyanov et al., 2004; Mann and Mody,
2010). In thalamus (Belelli et al., 2005; Cope et al., 2005; Bright
et al., 2007), dentate gyrus (Nusser and Mody, 2002) and cere-
bellum (Brickley et al., 1996), Itonic is maintained by the activity of
GABA receptors containing benzodiazepine insensitive v and/or a4
or a6 subunits (Brickley et al., 2001). However, Itonic may also be
mediated by receptors containing the a5 and v subunits (Clarkson
et al., 2010). In addition, a benzodiazepine-sensitive, presumably
non-v subunit mediated Itonic has been reported in hippocampal
neurons (Bai et al., 2001; Semyanov et al., 2003, 2004) and so-
matosensory cortex (Yamada et al., 2007). As Itonic is more active in
fast-spiking (FS) interneurons compared to pyramidal cells
(Semyanov et al., 2003), and FS cells have been reported to express
high levels of a1 subunit containing GABAA receptors (Bacci et al.,
2003; Thomson et al., 2000), an effect of benzodiazepines on Itonic
in a single FS cell could have a profound effect on synchronous
activity in neuronal networks.
Using magnetoencephalographic techniques we have recently
shown that cognitive and motor deﬁcits in stroke patients are
associated with slow wave (4e12 Hz) and beta (15e30 Hz) activity
in cortical regions, including M1 (Hall et al., 2010, 2014). Sub-
sedative doses of zolpidem reduce these, correlating with
improved clinical outcomes (Hall et al., 2010, 2014). Similarly, in
Parkinson's patients, we have shown that the power of inter-
hemispheric beta oscillations is unbalanced compared to controls,
such that beta power contralateral to Parkinsonian symptoms is
raised above ipsilateral beta power. The imbalance is reversed by
sub-sedative doses of zolpidem (Hall et al., 2014) through simul-
taneous augmentation and depression of contralateral and ipsilat-
eral beta power, respectively. These observations suggest that
zolpidem is capable of bidirectional modulation of neuronal
network activity in vivo. Here, using an in vitro brain slice model of
neuronal oscillatory activity and a kinetic model of GABAA receptor
dynamics, we show that changes in tonic inhibitory input to FS
interneurons produce bidirectional modulation of neuronal
network synchrony in M1 mediated by benzodiazepine-site
activation.
2. Materials and methods
2.1. Ethical approval
All procedures were approved by Aston University's Local Ethical Review Panel
and conducted in accordance with the Animals (Scientiﬁc Procedures) Act 1986 UK
and European Communities Council Directive 1986 (86/609/EEC).
2.2. Preparation of brain slices
Brain slices were prepared from male Wistar rats (40e60 g). Rats were anaes-
thetized with isoﬂurane and transcardially perfused with ice-cold artiﬁcial cere-
brospinal ﬂuid (aCSF; 100 ml) containing (in mM) sucrose (171), KCl (2.5), MgCl2
(10), NaHCO3 (25), 1.25 NaH2PO4, glucose (10), CaCl2 (0.5), ascorbic acid, 2 N-acetyl
cysteine (1), taurine (1) and pyruvate (20), and saturated with carbogen gas (95% O2/
5% CO2), at pH 7.3 and 310 mOsm. Indomethacin (45 mM), a cyclo-oxygenase in-
hibitor was added to the aCSF to improve cell viability (Pakhotin et al., 1997) and the
antioxidants ascorbic acid (300 mM) and uric acid (400 mM) added as
neuroprotectants.
The brain was removed, placed in ice-cold sucrose-based aCSF of similar
composition to that described above, and sagittal slices including M1 (450 mm for
extracellular recording, 350 mm for whole-cell recording) were cut at 5 C, using a
HM650 V microslicer and cooling unit (Microm GMBH, Germany). They were stored
in an interface chamber (for extracellular recordings) or a submersion chamber (for
whole-cell recordings), at room temperature (24 C), in oxygenated aCSF containing
(in mM) NaCl (126), KCl (3), MgSO4 (1.6), NaHCO3 (26), NaH2PO4 (1.25), glucose (10),
CaCl2, (2).2.3. Extracellular recordings
For extracellular recordings, slices were transferred to an interface chamber
(Scientiﬁc SystemDesign Inc, Canada) and continuously perfused (1e2ml/min) with
glucose-based aCSF. The perfusate was maintained at 33e34 C using a PTC03
proportional temperature controller (Scientiﬁc System Design Inc., Canada). Kainic
acid (KA,100 nM) and carbachol (CCh, 5 mM)were added to the perfusate to promote
network oscillatory activity. Wemeasured oscillatory power every 5 min and waited
until peak power had been within 10% variance for more than 30 min. Typically,
stabilization occurred after 60e90 min.
Local ﬁeld potential (LFP) recordings were made using borosilicate glass mi-
cropipettes ﬁlled with aCSF (1e3 MU; P-97, Sutter instrument Co, USA) and visually
positioned in layer V of M1. Signals were recorded and low-pass ﬁltered (200 Hz)
using a programmable signal conditioner (CyberAmp 380, Molecular Devices, USA).
Oscillatory activity was digitized at 10 kHz using an A-D converter (CED Micro-
1401 mk II; Cambridge Electronic Design, UK) and recorded to disk. Spike2 software
(CED, UK) was used for all acquisition and analysis.
2.4. Whole-cell recording
Slices were transferred to a submersion recording chamber perfused at 5e7 ml/
min with glucose-based aCSF at 32 ± 0.5 C, on the stage of an Olympus BX51WI
microscope. Layer V in M1 was readily identiﬁed by the presence of large pyramidal
(Betz) cells visualized using infrared video-microscopy with differential interference
contrast optics. Whole-cell recordings were made from cells visually identiﬁed as
non-pyramidal, using borosilicate glass pipettes (3e4 MU).
Current clamp recordings were made with an Axopatch 700A ampliﬁer (Mo-
lecular Devices, USA) using electrodes ﬁlled with a solution containing (in mM);
KMeSO4 (130), HEPES (10) EGTA (5), NaCl (4), Mg-ATP (4), Na-GTP (0.4), pH 7.2 at
295 mOsm. Membrane properties of putative FS cells were characterized electro-
physiologically using an incremental series of current steps (250 ms, from 400 pA)
until threshold for action potential ﬁring was reached.
For voltage-clamp recordings, electrodes were ﬁlled with a solution containing
(in mM); CsCl (100), HEPES (40), QX-314 (1), EGTA (0.6), MgCl2 (5) TEA-Cl (10), Na-
ATP (4,) Na-GTP (0.4) and IEM 1460 (1), titrated with CsOH to pH 7.25 at 295 mOsm.
This chloride-based solution allowed the study of inhibitory postsynaptic currents
(IPSCs) recorded at 70 mV using an Axopatch 700A ampliﬁer (Molecular Devices,
USA). Currents were ﬁltered at 5 kHz using a four-pole Bessel ﬁlter and were digi-
tized at 10 KhZ using pClamp version 10.3 (Molecular Devices, USA). Series resis-
tance was measured regularly via the capacitance transient induced during a line-
frequency voltage step (5 mV) during recording. Recordings where this changed
by >20% were omitted from analysis.
2.5. Data analysis
All data were analysed off-line using Clampﬁt 10.2 (Molecular Devices, USA),
Spike2 (CED, UK) or Mini-Analysis (Synaptosoft, USA). Spontaneous IPSCs (sIPSCs)
were analysed using Mini-analysis. The KolmogoroveSmirnov (KS) test was used to
assess changes in the cumulative probability distribution of inter-event intervals
(IEI) and Student's t-test was used to assess changes in IEI, decay time and ampli-
tude. To determine the effects of drugs on spontaneous release, 200 consecutive
sIPSCs were analysed from each recording in each condition (control v drug) and the
median value for interval, amplitude or decay calculated prior to ﬁnding a mean-
median value across multiple recordings.
In experiments involving application of GABA during whole-cell voltage clamp
recording, the rate and extent of desensitization of GABA-induced inward currents
was calculated by exponential curve ﬁtting, performed using a simplex algorithm







The ﬁt solves for the amplitude A, the time constant t, and the constant y-offset
C for each component i. The reduction in current after a long application of GABA
was taken as the steady-state level and calculated as a normalized value of the peak
current achieved.
For tonic current measurements, to exclude confounding effects of overlapping
sIPSCs, the baseline current was measured as described by Nusser and Mody (2002).
Brieﬂy, the mean of a 5-ms epoch was taken every 100 ms. The mean and SD of the
averaged baseline points were calculated for 10 s (~100 averaged baseline points) at
three distinct times of the recordings (periods A, B, and C). Two changes in the
baseline current were calculated between the three periods. The ﬁrst (DBL) was the
value of the difference during recording periods A and B, both taken during the
control period and reﬂecting baseline ﬂuctuation. The second (DDrug) was the value
of the difference during recording periods C and B, and reﬂecting drug induced
changes to the holding current. The two baseline changes (DBL and DDrug) were
then statistically compared (paired t-test).
The frequencyedomain method (Fast fourier transform (FFT)) was used to
generate power spectra of LFP data. Unless otherwise stated, 60 s epochs of sampled
data were analysed using Spike 2 (CED, Cambridge, UK). All statistical analyses were
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that are reported in the text.
All data are expressed as mean ± S.E.M. and * indicates signiﬁcance at P < 0.05, **
at P < 0.01 and *** at P < 0.001.
2.6. Source of drugs
Salts and other agents used in preparation of aCSF and electrode solutions were
obtained from Sigma (UK) and Fisher (UK). Bicuculline methobromide, gabazine,
zolpidem, THIP (4,5,6,7-Tetrahydroisoxazolo[5,4-c]pyridin-3-ol) hydrochloride) and
ﬂumazenil (8-Fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodi-
azepine-3-carboxylic acid) were obtained from Tocris, UK. Drugs were initially
prepared in stock solutions of 1e10 mM and stored at 20 C prior to dilution to the
ﬁnal concentration in aCSF immediately before use.
2.7. Modelling of GABAA receptor dynamics
Kinetic models were extended from previously published models of GABAA
receptor kinetics (Jones and Westbrook, 1995; Jones et al., 1998; Karayannis et al.,
2010), and, where possible, we have remained faithful to these. Models were
generated as ordinary differential equations (ODEs) using techniques described
previously (Croft et al., 2013) and the system solved using Matlab R2013b (Maths-
works) as follows: To simulate pre-incubation of tissue with either zolpidem or
ambient GABA, models were allowed to reach steady state (t0 ¼ 150 s). GABA was
then rapidly, but not discontinuously, increased to the speciﬁed concentration for
each experiment. Simulation of GABAA channels was calculated by measuring the
movement of Cl into the cell (see reaction scheme, Fig.10). To provide a comparison
with experimental data, we inverted the response measured to mirror changes in
tonic current observed within Cl loaded neurons. The concentration proﬁle was
modelled for 1 mM GABA at time t0 þ 200 s. To simulate the effects of adding zol-
pidem post GABA stimulation, 10 nM zolpidem was added at t0 þ 250 s. Where the
models previously generated by Jones and Westbrook (1995) have focused upon
single channel kinetics, our models used as many of these parameters as possible
and then adapted to show the possible mechanisms of the experimental data using
Matlab R2013b. The kinetic rate constants for parameters previously determined
experimentally were constrained, while the others were allowed to vary as the
software required. Initial conditions and reaction rate constants used in the
appropriate models are shown in Fig. 10C.
2.8. Model description e GABA
The model described here contains the same unbound state (U) and two tran-
sition states (B1 and B2) as published by Jones and Westbrook (1995) (see Fig. 10).
However, to describe the precise kinetics observed in our experimental datawe have
modiﬁed and extended this model to contain additional open and desensitized
states (depicted by the presence of the dotted boxes in Fig. 10). The Jones and
Westbrook (1995) model contains two open states (O1 and O2) and two desensi-
tized states (D1 and D2) both of which occur following GABA binding. Further to this,
we have proposed the existence of an additional open (O0) and desensitized state
(D0) both occurring from the unbound state (U; Wlodarczyk et al., 2013). To remain
consistent with the structure of the Jones and Westbrook model we have allowed
the single desensitized (D1) state to transition with the unbound desensitized state
(D0). As with the Jones and Westbrook models, the two-agonist binding sites are
assumed to be equal and independent.
2.9. Model description e zolpidem
To account for the actions of zolpidem binding, previous models of the GABAA
receptor kinetics have simply increased the rate with which GABA binds to its re-
ceptor (Kon). Here, additional parameters have been ﬁtted to ensure good agreement
with experimental data (Karayannis et al., 2010). Our initial attempts at using this
Kon modelling approach proved unsuccessful in reproducing our experimental data
shown in Fig. 11. As a consequence, primarily to reﬂect the non-intuitive data related
to the 10 nM zolpidem effect, we have derived a new kinetic model whereby we
allow zolpidem to be a reactant in the scheme. Based upon previous studies
(Pritchett et al., 1990; McKernan et al., 1995), zolpidem has been shown to bind to
GABAA receptors with higher or lower afﬁnity, depending on subunit expression of
the receptors. For simplicity, we have depicted this as a two-state binding event. The
ﬁrst is the higher afﬁnity state (UZ1) and the second, the lower afﬁnity state (UZ2).
Consistent with previous work, we assume that the presence of the bound zolpidem
decreases the Koff rate of GABA binding and increases the apparent frequency of
GABAA receptor channel opening (see Bianchi et al., 2009; Bianchi, 2010; see rate
constants Fig 10C). We next assumed that zolpidem binding is effectively irrevers-
ible due to its constant presence in the media. Finally, we assume that the kinetic
rate of GABAA channel opening is equal regardless of zolpidem or GABA bound
states, although it is well established that the frequency of opening of GABA re-
ceptors may be altered by benzodiazepine binding.
The reaction scheme for the zolpidem model is depicted in Fig. 10B. With zol-
pidem bound to the low afﬁnity site (UZ2), GABA is nowable to bind and the channel
transitions through the states analogous to that shown for the GABA binding model.
Where possible, the rate constants have been conserved between the two models,however, to account for changes in receptor dynamics brought about by the binding
of zolpidem, new rate constants were attributed as shown in Fig. 10C.2.10. Initial conditions and rate constants used in simulating experimental
conditions
The initial concentration of species in the model was, U 5 mM, Clout 130 mM,
Clin 0.9 mM and ambient GABA 100 nM. Both concentrations of ambient GABA and
Clout remained constant through all simulations to reﬂect experimental conditions.
Zolpidem concentrations were varied as stipulated in each simulation. For the ma-
jority of simulations 1mMGABAwas used as the simulating ligand unless stated. The
rate constants usedwere ﬁxedparameterswhen simulating experimental conditions.3. Results
3.1. Involvement of GABA and benzodiazepine binding in beta-
oscillations
Previous studies indicate that GABAA receptors containing a1
and g2 subunits are present on inhibitory interneurons, including
FS cells. Since the benzodiazepine-binding site lies at the interface
between these subunits, and GABAergic interneurons are subject to
cell-type speciﬁc GABA tone, we hypothesized that
benzodiazepine-site activation would act, via GABAergic in-
terneurons, to modulate oscillatory activity.
We generated persistent oscillations at ‘beta’ (high beta/low
gamma) frequency (Fig. 1A; mean peak frequency 30.1 ± 0.5 Hz;
mean power 119.9 ± 16.5 mV2, n ¼ 128) in slices of M1 by appli-
cation of KA (100 nM) and CCh (5 mM). We ﬁrst tested for
involvement of GABAergic mechanisms. Application of the GABAA
receptor antagonist gabazine (250 nM) reduced modal peak beta
oscillatory power to 49.0 ± 8.2% of baseline and cumulative appli-
cation of gabazine to 2 mM further reduced beta power to
32.4 ± 4.6% of baseline (P < 0.001 in both cases, n ¼ 10, see Fig. 1B).
Further involvement of GABAergic mechanisms was conﬁrmed by
application of the GABA uptake blocker, tiagabine (1 mM) (Fig. 1C),
which enhanced modal peak oscillatory power (180.7 ± 24.7% of
control, <0.05, n ¼ 6). Interestingly, a higher concentration of tia-
gabine (10 mM) depressed modal peak power (80.2 ± 25.4% of
control, P < 0.01, n ¼ 6).
To investigate the role of the benzodiazepine site in modulation
of beta oscillations, we tested the effects of the benzodiazepine-site
agonist, zolpidem. In previous in vitro studies, zolpidem has often
been used at mM concentrations (e.g. Palhalmi et al., 2004; Koniaris
et al., 2011). We have reported that zolpidem depresses neuronal
oscillatory activity in vivo in the cortex of stroke (Hall et al., 2010)
and Parkinson's disease (Hall et al., 2014) patients at sub-sedative
doses (5 mg). Plasma concentration after oral administration of
5e10 mg of zolpidem is in the range of 14e93 ng/mL (Olubodun
et al., 2003; Greenblatt et al., 2006). Zolpidem is approximately
92% bound by plasma proteins (Salva and Costa, 1995), suggesting
that the effective concentration of zolpidem in vivo may be in the
nM range; hence we chose to explore the effects of low nanomolar
concentrations of zolpidem in vitro.
Consistent with our observations in vivo, zolpidem at 10 nM
robustly depressed modal peak beta power (to 60.2 ± 6.8% of
control, P < 0.001, n ¼ 21; Fig. 2).
It is generally accepted that benzodiazepine site agonism causes
an enhancement of beta activity or ‘beta buzz’ (Glaze, 1990), so we
explored the dose-dependency of benzodiazepine-site modulation
by constructing cumulative dose response curves (30e500 nM). In
contrast to the depression of beta power with 10 nM zolpidem, an
enhancement was seen at 30 nM (319.2 ± 119.9%, P < 0.05, n ¼ 7;
Fig. 3). We repeatedly attempted to construct concen-
trationeresponse curves for the complete range of concentrations
from 10 to 500 nM. However, we found that once oscillatory power
Fig. 1. Beta oscillations in M1 are dependent on GABAergic inhibition. Ai) Mean frequency and power of beta oscillations in M1. Aii) Representative power spectrum of beta activity
in M1 in vitro. Bi) Raw data traces showing typical effects of gabazine (250 nM and 2 mM) on oscillatory activity in M1. Bii) Pooled data showing change in peak beta power in the
presence of gabazine and representative power spectra. Ci) Raw data traces showing typical effects of tiagabine (1 mM and 10 mM) on oscillatory activity in M1. Cii) Pooled data
showing change in peak beta power in the presence of tiagabine and representative power spectra. Scale bars 200 ms  50 mV. *P < 0.05, **P < 0.01, ***P < 0.001.
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augment oscillatory power with higher concentrations.
Zolpidem clearly had two discernible effects, with reduction of
oscillatory power at 10 nM and clear augmentation at 30 nM. At
higher concentrations (100e500 nM), the drug began to depress
beta power again, but this effect was quite variable, so we focused
further experiments on the repeatable effects of zolpidem at 10 and
30 nM.
In view of the narrow concentration threshold between inhibi-
tion and augmentation of oscillatory activity, we examined thebenzodiazepine-site speciﬁcity of the different effects of zolpidem,
by repeating the previous experiments in the presence of a
benzodiazepine-site antagonist. Flumazenil (500 nM), prevented
both the depressing and potentiating effects of zolpidem (Fig. 4Ai
and Aii). This indicates that zolpidem exerts both effects on beta
power through the benzodiazepine binding site. Interestingly,
application of ﬂumazenil alone signiﬁcantly augmented oscillatory
power (276.7 ± 111.4% of control at 100 nM, 292.1 ± 90.8% at
200 nM and 273.2 ± 90.0% at 500 nM, n ¼ 6, P < 0.05, Fig. 4Bi and
Bii).
Fig. 2. 10 nM zolpidem reduces beta oscillatory power. A) Raw data traces showing the
reduction in oscillatory activity induced by bath application of zolpidem at 10 nM. B)
Bar charts of pooled data showing a reduction in beta oscillatory power induced by
zolpidem (10 nM). C) Representative power spectra. Scale bars 200 ms  50 mV.
***P < 0.001.
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currents
We have recently reported a depression of pathological theta/
beta oscillations associated with alleviation of stroke related deﬁ-
cits in cognitive function (Hall et al., 2010), by sub-sedative doses of
zolpidem in a stroke patient. Similarly, we have described beneﬁts
of low-dose zolpidem treatment in patients with Parkinson's dis-
ease (Hall et al., 2014). Thus, the inhibition of beta activity by zol-
pidem at a low concentration (10 nM) was of particular interest.
Zolpidem could alter phasic and/or tonic inhibition GABAergic in-
hibition (Nusser and Mody, 2002; Semyanov et al., 2003; Gao and
Smith, 2010), so we investigated these possibilities in pyramidal
and FS interneurons in M1.3.2.1. Tonic and phasic inhibition in pyramidal cells
Wemadewhole-cell voltage clamp experiments frompyramidal
neurons in layer V. To establish whether the effects of zolpidemwe
saw in LFP recordings of network activity were related to GABAergic
neuronal activity we recorded sIPSCs, which reﬂect inhibitory ac-
tivity from local networks of GABAergic neurons. Fig. 5 shows that
application of KA and CCh elicited rhythmic sIPSCs at beta (and
lower) frequency, evidenced as a peak at 15e20 Hz in the fast
Fourier transform of the data. Addition of zolpidem (Fig. 5B)signiﬁcantly depressed peak beta power, (P < 0.05; n ¼ 6; Fig. 5C).
Mean area power (between 13 and 29 Hz) was 64.7 ± 27.9 pA s,
increasing to 521.4 ± 302.1 pA s in KA and CCh and decreasing to
327.9 ± 86.1 pA s in zolpidem. Although beta frequency in sub-
merged recording conditions was lower than that seen in interface
LFP recordings, it was clear that zolpidem had a similar effect at low
concentrations, and that these effects were related to rhythmic
inhibitory activity generated by GABAergic neurons impinging on
principal cells.
A change in rhythmic sIPSCs could be attributable to a direct
reduction in presynaptic release of GABA, inhibition of postsynaptic
receptors, or indirect reduction of GABA release via depression of
interneuronal excitability, and might be mediated via phasic or
tonic inhibition on principal cells or interneurons. We explored
these possibilities using zolpidem at concentrations found to either
depress or augment beta oscillatory power.
In voltage clamp recordings from pyramidal cells, a tonic current
(mean 14.7 ± 4.8 pA, n ¼ 13) was revealed by blockade of GABAA
receptors with bicuculline (20 mM). Zolpidem (10 nM) had no sig-
niﬁcant effect on Itonic (2.4 ± 6.6 pA, P > 0.05, n ¼ 6). Zolpidem also
failed to modulate Itonic at 30 nM (mean change 2.3 ± 7.4 pA,
P > 0.05, n ¼ 7). These data suggested that pyramidal cell Itonic was
zolpidem-insensitive. We also examined the kinetics of sIPSCs
recorded in pyramidal neurons during application of 10 and 30 nM
zolpidem, and found no signiﬁcant change in mean-median IEI,
amplitude or decay time constant, indicating that phasic inhibition
in pyramidal cells is also unaffected by zolpidem at the concen-
trations used (See Supplementary ﬁgures for analyses of tonic and
phasic currents in pyramidal cells).3.2.2. Phasic inhibition in FS cells
In order to address similar questions in FS cells, Betz cells in
layer V were ﬁrst located on the basis of size, orientation and
morphology, and FS cells then identiﬁed through their own char-
acteristic morphology and location adjacent to Betz cells (Fig. 6A).
The stereotypical arrangement between Betz and GABAergic in-
terneurons was conﬁrmed, as previously reported (Ali et al., 2001;
Ali, 2003). In FS cells (n ¼ 6) depolarizing current injection, elicited
high frequency (80e198 Hz) non-adapting spikes with short
duration at half amplitude (0.76 ± 0.03 ms), a pronounced medium
after-hyperpolarization (AHP; 17.4 ± 1.6 mV) with no slow AHP, and
a mean input resistance of 99.0 ± 6.0 MU (Fig. 6B). There was no
evidence of a depolarizing sag in the response to hyperpolarizing
current injection. These characteristics are similar to those
described previously for FS cells in M1 (Kawaguchi, 1995; Cauli
et al., 1997; Kawaguchi and Kubota, 1997; Ali et al., 2001). In sub-
sequent studies we used voltage-clamp recording to assess phasic
and tonic GABAergic inhibitory currents in FS neurons.
We showed above that gabazine (250 nM) inhibited beta oscil-
lations in LFP recordings. In FS neurons, gabazinemarkedly reduced
sIPSC amplitude from 18.7 ± 5.0 pA to 11.8 ± 2.0 pA (P < 0.05; n¼ 6)
and mean IPSC decay time was reduced from 6.1 ± 1.0 to
4.4 ± 1.0 ms (P < 0.05). A tendency towards increased IEI
(201 ± 72 ms v 380 ± 214 ms) did not reach signiﬁcance (see
Supplementary ﬁgures).
We found that low concentrations of zolpidem had no
discernible effect on sIPSCs Thus; zolpidem (10 nM) had no effect
on the distribution of IEI (mean 343.9 ± 124.4ms v 250.0 ± 75.5ms;
P > 0.05, KS) or amplitude of sIPSCs (mean 47.7 ± 4.2 pA v
48.0 ± 2.1 pA; P > 0.05, KS) in FS neurons (n ¼ 6). Decay time
(10e90%) was also unaffected (6.7 ± 1.1 ms v 6.2 ± 0.83 ms;
P > 0.05). Similar observations were made with 30 nM zolpidem
(see Supplementary ﬁgures).
Fig. 3. Concentration-dependent modulation of oscillatory power by zolpidem. A) Raw data traces showing the effect of different doses of zolpidem (30e500 nM) on beta
oscillatory activity. B) Bar chart of pooled data showing a reduction in beta oscillatory power induced by zolpidem (30e500 nM). C) Representative power spectra. Scale bars 200
ms  50 mV. *P < 0.05.
Fig. 4. Flumazenil (500 nM) blocks zolpidem induced depression and augmentation of beta power. Ai) Pooled data showing ﬂumazenil blockade of the effects of zolpidem at 10 and
30 nM on modal peak beta oscillatory power. Aii) Power spectra of typical data recorded during ﬂumazenil blockade of zolpidem responses. Bi) Bar chart showing effects of
increasing concentration of ﬂumazenil on beta power. Bii) Representative power spectrum showing increase in oscillatory power obtained in ﬂumazenil (100e500 nM). Scale bars
200 ms  50 mV. *P < 0.05.
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Given that we could ﬁnd no effect of 10 nM zolpidem on phasic
inhibition impinging on GABAergic neurons in M1, we analysed the
effects of zolpidem application on tonic inhibition. Since tonic in-
hibition has not previously been demonstrated in FS cells in M1, we
ﬁrst tested the effects of the competitive GABAA receptor antago-
nist, gabazine (250 nM). As Fig. 6C shows, gabazine revealed a toniccurrent (mean 10.3 ± 4.4 pA, P < 0.05 compared to baseline ﬂuc-
tuation; n ¼ 5). Subsequent co-application of bicuculline (20 mM)
removed the small residual current, although overall there was no
signiﬁcant change compared to gabazine alone (2.5 ± 2.3 pA).
Application of bicuculline alone (20 mM), as Fig. 6D shows, also
caused a decrease in holding current (22.66 ± 3.55 pA, n ¼ 6,
P < 0.001). These data indicated that a tonic current was indeed
Fig. 5. Zolpidem reduces rhythmic IPSC activity in FS cells. A) Raw traces showing the
effects of zolpidem on KA þ CCh induced sIPSC activity in an FS cell. Scale bars 500
ms  200 pA. B) Power spectrum (30 data segments) from the recording in A), showing
effects of zolpidem on spectral power. C) Pooled data showing effects of zolpidem
(10 nM) on area power at 15e29 Hz. *P < 0.05.
Fig. 6. Identiﬁcation of FS interneurons. A) Photo-micrograph showing recording
electrode and putative FS interneuron (asterisk) in close proximity to Betz cells (ar-
rows) in LV of M1. Scale bar 25 mm. B) Voltage traces of the FS cell identiﬁed in A), in
response to 400 pA and þ100 pA current steps. Scale bars 25 mV, 50 ms. Note the
high ﬁring frequency (>100 Hz) and action potentials with large AHPs. C) Represen-
tative voltage-clamp recording from a FS interneuron at a holding potential of 70 mV
during application of gabazine (250 nM) and bicuculline (20 mM). Scale bar 100 pA,
2 min. D) Representative voltage-clamp recording from a FS interneuron at a holding
potential of 70 mV during application of bicuculline alone. Scale bar 100 pA, 2 min.
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tivity of Itonic to zolpidem. At 10 nM, zolpidem itself generated a
slow, inward current (mean amplitude 15.0 ± 3.5 pA; n ¼ 6;
Fig. 7A,D). Subsequent application of bicuculline (20 mM) abolished
Itonic suggesting that the increase in inward current by zolpidem
was due to augmentation of existing Itonic. Indeed, bicuculline al-
ways reduced Itonic beyond the pre-zolpidem baseline, showing the
presence of a non-zolpidem induced component of tonic current in
the inhibitory neurons. To determine whether two components
could be differentiated, we attempted to modulate Itonic through
alteration of ambient GABA concentration. We pre-applied GABA
(1 mM), which induced in a large inward current (70.0 ± 14.1 pA;
n¼ 6, P < 0.05; Fig. 7B,D). Subsequent addition of zolpidem (10 nM)
generated a further inward current, of the same magnitude as thatseen without addition of GABA (14.9 ± 5.1 pA; P < 0.05; Fig. 7B,D),
suggesting that at 10 nM, the Itonic induced by zolpidem did not
depend on ambient GABA concentration.
Previous reports have indicated that Itonic is often linked to the
presence of the delta (d) subunit within extrasynaptic GABA re-
ceptor complexes (Nusser et al., 1998) so we studied the subunit
composition of receptors mediating Itonic in FS cells using the d-
subunit-selective agonist, THIP. THIP has been reported to be se-
lective for d-subunit containing receptors at up to 800 nM (Meera
et al., 2011), so we used a slightly higher concentration of THIP
(1 mM) look for occlusion of the zolpidem mediated augmentation
of Itonic. THIP alone had no effect on phasic inhibition (data not
shown) but did induce a slow inward current in FS cells (Fig. 7C,D).
After stabilization of the THIP-induced current (mean
17.1 ± 11.6 pA; n ¼ 6), a further increase in Itonic was induced by co-
application of zolpidem at 10 nM (14.9 ± 6.7 pA), and the difference
was signiﬁcant (Fig. 7C,D; P < 0.05). These data suggest that a pool
of THIP-sensitive, d-subunit containing receptors mediates a
component of Itonic in FS cells, but that these receptors are not the
same as those mediating the effects of zolpidem.
Finally, it should be noted that when bicuculline (20 mM) was
applied prior to zolpidem, both phasic and tonic inhibition were
abolished, and changes in holding current in response to zolpidem
were not seen (n¼ 6, data not shown), indicating that both forms of
Itonic were mediated by bicuculline-sensitive GABAA receptors.3.3. Effects of benzodiazepine site antagonism on tonic and phasic
inhibition in FS cells
We further examined the role of the benzodiazepine site on the
effects of zolpidem using the antagonist ﬂumazenil. Flumazenil
(500 nM) had no effect on phasic inhibition (Fig. 8A,B). Themean IEI
of sIPSCs in control was 416.5 ± 14.7 ms compared to
488.5 ± 19.6 ms in ﬂumazenil (n ¼ 6; P > 0.05 KS), and sIPSC
amplitude was also unaltered (81.8 ± 1.4 pA v 80.0 ± 1.4 pA;
P > 0.05 KS).
Fig. 7. Zolpidem (10 nM) augments a tonic inhibitory current in FS interneurons. A) Representative recording showing zolpidem (10 nM) induction of Itonic. Subsequent addition of
bicuculline (20 mM) abolished both phasic IPSCs and zolpidem-induced tonic current. Scale bar 50 pA, 2 min. B) Representative recording showing a GABA and zolpidem induced
tonic current. Note that the GABA current is desensitizing, but the zolpidem current is not. Scale bars 100 pA, 5 min. C) Voltage-clamp recording from an FS interneuron at a holding
potential of 70 mV. Addition of THIP (1 mM) induced a tonic current. Subsequent addition of zolpidem (10 nM) augmented the current and the effect of both drugs was blocked by
bicuculline (20 mM). Scale bar 100 pA, 2 min D) Histogram showing mean change in holding current induced by zolpidem (10 nM), GABA (1 mM), GABA (1 mM) þ zolpidem (10 nM),
bicuculline (20 mM) alone, THIP and further changes induced by co-addition of zolpidem. *P < 0.05, **P < 0.01.
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current (31.3 ± 13.9 pA; P < 0.01, n ¼ 6), demonstrating that Itonic in
FS cells depends on benzodiazepine-site activity. If the inhibitory
effects of zolpidem on beta oscillations were mediated via the
zolpidem-sensitive tonic current in FS cells, thenwemay expect the
zolpidem (10 nM) induced augmentation of Itonic to be blocked by
ﬂumazenil. This was indeed the case, as when zolpidem (10 nM)
was applied in the presence of ﬂumazenil no further change in
holding current was observed (Fig. 8C).
3.4. Effects of 30 nM zolpidem on phasic and tonic inhibition in FS
cells
As described above, 30 nM zolpidem elicited an increase in
oscillatory power, suggesting that the higher concentration may
have an additional effect on phasic inhibition, and/or a different
effect on Itonic., so we explored the effects of zolpidem at 30 nM on
phasic and tonic inhibition in FS cells. Zolpidem at 30 nM, as at
10 nM, had no effect on IEI, amplitude or decay time of sIPSCs (data
not shown). However, in contrast to its effects at 10 nM where it
augmented Itonic, at 30 nM zolpidem elicited a decrease in Itonic
(17.8 ± 20.4 pA; P < 0.05; n ¼ 6; Fig. 9A,C).
3.5. The role of desensitization in the differential effects of zolpidem
in FS cells
Since the effects of benzodiazepine site ligands might be ex-
pected to differ depending on receptor occupancy, and since both
occupancy and benzodiazepine bindingmight alter GABAA receptor
dynamics such as desensitization and resensitization, we recordedItonic under conditions in which GABA concentration was ﬁxed at a
sub-saturating level of 1 mM. At 1 mM (Fig. 9B,C), GABA induced a
maximum inward current (78.62 ± 47.5; P < 0.05; n¼ 6) and steady
state desensitization (28.3 ± 7.6; P < 0.05). In contrast to its effects
at ambient GABA levels, application of 30 nM zolpidem in the
presence of 1 mMGABA, elicited an increase in Itonic (82.3 ± 37.6 pA;
P < 0.05; n ¼ 6; Fig. 9B,C) and this was followed by rapid desen-
sitization of the zolpidem-induced response (28.3 ± 7.6 pA). The
large increase in tonic current and the desensitization proﬁle
observed in the presence of 1 mM GABA suggested that a robust
desensitization process was taking place.
Using the kinetic simulationmodel described in themethodswe
have simulated the experimental data described above. The model
contains the presence of open and desensitized states for the un-
bound receptor and clearly shows the opposing effects of low and
higher dose zolpidem. Fig. 10 shows the Markov models for GABA
(Fig. 10A) and zolpidem (Fig. 10B) binding; the rate constants used
(Fig. 10C) were ﬁrst estimated using the parameters of Jones and
Westbrook (1995).
As Fig. 7A showed, zolpidem at 10 nM caused an increased
Itonic. In the kinetic model, this behaviour was also seen
(Fig. 10Di). By contrast, zolpidem caused a decrease in Itonic at
30 nM (Fig. 9A), and again this was captured in the behaviour of
the model (Fig. 10Dii), with the distribution of receptor-ligand
states suggesting that this is related to enhanced entry into
rapidly desensitized states. When we ‘applied’ zolpidem in the
presence of 1 mM GABA in the model (Fig. 10Diii), 30 nM zolpi-
dem caused a clear (and relatively large) increase in Itonic fol-
lowed by a clear desensitization, analogous to the situation
shown in Fig. 9B.
Fig. 8. Flumazenil (500 nM) reduces the tonic inhibitory activity and blocks the zolpidem-induced tonic current in FS interneurons. A) Representative traces from single experiment
showing sIPSCs in control and ﬂumazenil (500 nM). Scale bars 50 pA  500 ms. Bi) Cumulative probability plot showing there was no signiﬁcant change in the frequency of sIPSCs
with the addition of ﬂumazenil (500 nM). Bii) Cumulative probability plot showing there was no signiﬁcant difference to sIPSC amplitude with the addition of ﬂumazenil (500 nM).
C) Representative voltage-clamp recording from a FS interneuron at a holding potential of 70 mV. Addition of ﬂumazenil (500 nM) slowly reduced a tonic current. Subsequent
addition of zolpidem (10 nM) was without effect. Scale bars 100 pA, 5 min.
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tration of 10 nM, zolpidem induces a consistent, low amplitude
Itonic that is independent of ambient GABA concentration. By
contrast, at 30 nM, zolpidem induces changes in Itonic whoseFig. 9. Zolpidem (30 nM) inhibits tonic current without effect on phasic IPSCs in FS
interneurons. A) Voltage-clamp recording from an FS interneuron at a holding po-
tential of 70 mV. Addition of zolpidem (30 nM) reduced a tonic current. Scale bar
100 pA, 5 min. B) Voltage-clamp recording from an FS interneuron. Addition of GABA
(1 mM) induced a large inward current, which was increased by further addition of
zolpidem (30 nM). Note the desensitization of the tonic current that takes place in both
GABA and zolpidem. Scale bar 100 pA, 1 min. C) Bar chart showing change in holding
current induced by the addition of zolpidem (30 nM), GABA (1 mM) and GABA
(1 mM) þ zolpidem (30 nM). *P < 0.05.magnitude and even direction is highly dependent on ambient
GABA. We interpreted these data to indicate that at 10 nM, zol-
pidem falls below the threshold for exerting effects on GABA re-
ceptor afﬁnity, instead working to enhance channel opening
through effects on gating in a subpopulation of GABA receptors. At
30 nM, zolpidem begins to affect the GABA unbinding rate, and
this is manifest as a greatly enhanced Itonic in the presence of 1 mM
GABA, which was as large as the current induced by 1 mM GABA
itself. These afﬁnity effects are also manifest as rapid desensiti-
zation events, seen clearly at 30 nM in the presence or absence of
applied GABA.
The experimentswith 30nMzolpidem indicated that at different
concentrations of zolpidem and ambient GABA, we were observing
differences in the rate and extent of steady state desensitization of
GABA receptors on FS cells. Entry into and out of desensitized states
is controlled, at least in part, through the degree of binding of the
GABA receptor. For example, at synaptic levels of GABA, desensiti-
zation is rapid, and exit and entry to and fromopen and desensitized
states play amajor role in shaping the decay phase of the GABA IPSC.
At lower levels of GABA, however, receptor occupation is unlikely to
be high, and channel kinetics are altered. Recently, an elegant study
of receptors modiﬁed to disable dual binding (Petrini et al., 2011)
reported that mono-liganded GABA receptors showed dramatically
slowed kinetics compared to dual bound receptors, and that entry
andexit fromdesensitizationwasparticularly slowat very lowlevels
of receptor occupancy. We hypothesized that, in the presence of
nanomolar ambient GABA and 10 nM zolpidem, receptor binding
would be low and effects of zolpidem on Koff would be negligible,
such that slowentryandexit fromadesensitized state similar to that
described byPetrini et al. (2011)would be favoured. By contrast, this
would not be so at 30e1000 nM, when effects on Koff dominate, and
when zolpidem induced rapid desensitization would be readily
observed (as in Fig. 9B) and may even be enhanced by benzodiaze-
pine binding (Mellor and Randall, 1997). Benzodiazepine site
mediated effects on Koff cannot affect themaximal rate and extent of
responses to saturating concentrations of GABA (Bianchi et al., 2009;
Fig. 10. Simulation of experimental data. A) Markov model containing unbound state (U) and two transition states (B1 and B2), two open states (O1 and O2) and two desensitized
states (D1 and D2) both of which occur following GABA binding. Further to this, we have proposed the existence of an additional open (O0) and desensitized state (D0) both occurring
from the unbound state (dashed boxes in scheme). B) Model accounting for zolpidem binding depicted this as a two-state binding event. The ﬁrst is a higher afﬁnity state (UZ1) and
the second, a lower afﬁnity state (UZ2). O and D refer to open and desensitized states, respectively. C) Rate constant table for the schemes in A and B. Di) Simulation of experimental
data in Fig. 3B (10 nM zolpidem). Dii) Simulation of experimental data in Fig. 5A (30 nM zolpidem). Diii) Simulation of experimental data in Fig. 5B (30 nM zolpidem in 1 mM GABA).
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fects on GABA receptors primarily through effects on mono- or
unliganded, kinetically slowentry and exit fromdesensitized states,
this would be revealed as a submaximal response to challenge with
saturating GABA.
We therefore tested for a population of kinetically slow
desensitized GABAA receptors by pre-incubating in 10 nM,
30 nM or 1 mM zolpidem and subsequently challenging with
saturating (1 mM) GABA in the continued presence of zolpi-
dem. Application of 1 mM GABA alone typically elicited a large
inward current (976.9 ± 184.1 pA, n ¼ 8), followed by
desensitization (t 19.74 ± 1.37 s, extent 366.4 ± 96.50 pA,
n ¼ 8), to a steady-state (478.7 ± 197.3 pA, n ¼ 8). We thenmeasured the maximal and steady-state current, and the rate
and extent of desensitization in a series of experiments in
which GABA (1 mM) was applied after pre-incubation (for
60 min) in different concentrations of zolpidem. Zolpidem was
also present in the bath at the pre-incubation level for the
duration of the experiment. As Fig. 11 shows, at both 30 nM
and 1 mM, the effects of saturating GABA were not signiﬁcantly
different to control (n ¼ 6 in each group), with large maximal
current, rate and extent of desensitization and steady-state
values. Indeed, discernible changes to the desensitization pa-
rameters were only visible after pre-incubation with 10 nM
zolpidem. Here, the application of GABA resulted in much
reduced maximal and steady-state currents and a lesser rate
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(Fig. 11Ai&B, 10 nM zolpidem; maximum current
448.7 ± 54.93 pA, t 71.19 ± 21.43 s, extent 127.3 ± 29.99 pA,
steady-state 142.3 ± 26.56 pA, P < 0.05, n ¼ 6). Summary data
are presented in Fig. 11B). These data strongly suggest that a
population of receptors was sequestered into a kinetically slow
desensitized state by incubation with 10 nM zolpidem and that
such receptors were then unavailable to participate in further
desensitization processes. We tested this hypothesis using an
in silico approach, applying a ‘saturating concentration’ of
GABA in a model that allowed analysis of the individual re-
ceptor species concentrations after pre-incubation with
different ‘zolpidem concentrations’.
When we repeated the experiments in silico, the model showed
a proﬁle consistent with the in vitro data, such that GABA induced a
large peak and desensitization to a steady-state. Hence, control,
30 nM and 1 mM zolpidem simulations showed extensive desen-
sitization, with large ‘currents’ and rapid kinetics. In excellent
agreement with the in vitro experiments, 10 nM zolpidem occluded
these effects to a signiﬁcant degree (Fig.11Aii). Themodel predicted
a reduction in the population of receptors immediately available for
maximal activation and desensitization in response to 1 mM GABA.
Analysis of the individual receptor species concentrations revealed
that after incubationwith 10 nM zolpidem, 54.9% of GABA receptors
were unavailable for binding in 1 mM GABA, compared to only
12.1% of receptors following incubation in 1000 nM zolpidem.Fig. 11. Zolpidem (10 nM) blocks fast desensitization processes in FS interneurons. Ai) Voltag
zolpidem (blue) have differing effects on desensitization processes. Aii) Simulation of experim
GABA after pre-incubation with zolpidem (10, 30, 1000 nM). Bii) The steady state response i
desensitization is signiﬁcantly increased and Biv) the amplitude of desensitization is signiﬁ
interpretation of the references to colour in this ﬁgure legend, the reader is referred to theHence, the kinetically slow desensitization produced by 10 nM
zolpidem incubation appeared to have prevented GABA binding
during the challenge with saturating GABA, whilst higher concen-
trations of zolpidem favoured kinetically rapid transitions between
states and allowed z90% of receptors to bind GABA and become
rapidly desensitized.
4. Discussion
4.1 Beta oscillations and FS interneurons in M1
FS cells preferentially form synaptic connections at perisomatic
and proximal dendritic regions of numerous neighbouring pyra-
midal cells, and are thus able to exert powerful control over large
assemblies of neurons (Cobb et al., 1995). The characteristic fea-
tures of FS cells, which include short duration action potentials,
high frequency ﬁring with no adaptation, reliable synchronous
GABA release and rapidly decaying IPSPs onto principal cells,
mediated by receptors containing the a1 subunit (Thomson et al.,
2000), appear crucial for both coherence of network oscillations
and frequency control (Bartos et al., 2001, 2002). Recently, Manseau
et al. (2010) have reported the asynchronous release of GABA at
autaptic and synaptic contacts from FS interneurons, highlighting
the fact that these cells control both synchronization and
desynchronization processes in cortical networks and underlying
their pivotal position in network function.e-clamp traces showing pre-incubation of slices in 10 nM (grey), 30 nM (red) and 1 mM
ental data in Bi. Bi) Bar chart showing maximum current induced by addition of 1 mM
s reduced after pre-incubation with zolpidem (10 nM). Biii) The decay time constant of
cantly reduced after pre-incubation with zolpidem (10 nM). *P < 0.05, **P < 0.01. (For
web version of this article.)
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In addition to phasic synaptic inhibition, CNS neurons are also
subject to persistent, tonic inhibition. Due to the substantial charge
transfer associated with tonic inhibition, its effects are profound
and include altering excitability of individual neurons as well as
inﬂuences on excitatory synaptic efﬁcacy and integration (Farrant
and Nusser, 2005). It has been demonstrated that differential
regulation of GABA uptake (Semyanov et al., 2003) enhances Itonic
FS cells compared to that seen in pyramidal cells. Hence, Itonic in FS
cells appears likely to exert powerful control over network activity,
and, indeed, eliminating tonic inhibition in interneurons has been
shown to increase the power of gamma activity in CA1/CA3 of the
hippocampus (Mann and Mody, 2010).
In agreement with studies in other areas, we found Itonic in all
our recordings from FS cells in M1. Our results show that Itonic in FS
cells is increased by 10 nM zolpidem, but that the opposite effect is
seen at 30 nM. At these two concentrations, zolpidem has opposing
effects on the power of beta oscillations in M1 and, given the strong
relationship between FS cell function and network activity, it seems
likely that the bidirectional effects on Itonic and on network oscil-
latory power are related. The actions of ﬂumazenil in blocking Itonic
and enhancement of oscillatory power in M1 further supports this
interpretation. The benzodiazepine site has been implicated in
modulation of neuronal network oscillations (Palhalmi et al., 2004)
and a zolpidem-sensitivity of Itonic has also been reported in other
areas, albeit at considerably higher concentrations (Semyanov et al.,
2003; Gao and Smith, 2010). The actions of zolpidem at the low
concentrations described above may involve subunit-speciﬁc ef-
fects. When tested on recombinant receptors, zolpidem displayed a
high potency at a1-containing GABAA receptors (a1b2g2, a1b3g2:
Ki ¼ 20 nM). Zolpidem had medium potency at a2 and a3 con-
taining GABAA receptors (e.g. a121g2, a3b1g2: Ki ¼ 400 nM) and
was ineffective at a5 subunit containing receptors (a5b3g2,
a5b2g2: Ki 5000 nM) (Langer et al., 1992; Pritchett and Seeburg,
1990). The effects of very low concentrations of zolpidem on Ito-
nic, in our data strongly suggest that the GABAA receptors mediating
the current in FS cells in M1 contain the a1 subunit (Pritchett and
Seeburg, 1990; Langer et al., 1992; Crestani et al., 2000). This does
not preclude the inclusion of d subunits, believed to account for
most of the Itonic observed in other neurons (Brickley et al., 1996;
Nusser and Mody, 2002; Belelli et al., 2005; Cope et al., 2005;
Bright et al., 2007). Indeed, when we pre-applied the d-subunit
selective agonist, THIP, we found no occlusion of zolpidem induced
augmentation of Itonic, suggesting that non-desensitizing, d-subunit
containing receptors were not primarily involved in the response to
zolpidem. This is consistent with our earlier experiments (Fig. 5) in
which bicuculline blocked both the tonic current induced by 10 nM
zolpidem and also a further, presumably zolpidem-insensitive,
component.
Our data showed that application of zolpidem augmented an
existing Itonic in FS cells, indicated by the reduction of Itonic beyond
baseline by bicuculline. These data conﬁrm previous reports
(Semyanov et al., 2003) of a strong Itonic at ambient GABA levels in
FS cells in CA1 in the absence of uptake inhibitors. Moreover, the
effect of ﬂumazenil on both zolpidem-induced and baseline Itonic
suggests that in these cells the current depends on endogenous
activation of the benzodiazepine site, as described recently by
Christian et al. (2013).
That we found no effects of low concentrations of zolpidem on
phasic inhibition indicates that the dual effects of zolpidem on
neuronal network oscillations in M1 may be mediated via tonic
inhibition alone. In support of this interpretation, Wulff et al.
(2009) have recently reported that knockout of GABAA receptors
on parvalbumin positive FS cells in hippocampus does not altergamma activity, suggesting that extrasynaptic inhibitory drive may
be more important than previously thought. The reduction in Itonic
seen with 30 nM zolpidem might be predicted to increase the
number or effectiveness of FS cells participating in network activity,
suggesting that the benzodiazepine-site may be involved in scaling
the size of the active network.
What receptor states may underlie the behaviour of Itonic in
response to different degrees of benzodiazepine-site agonism? In
our basic model, a population of closed, unbound receptors (U)
exists in equilibrium with a population of closed, bound receptors
(B1 and B2), and the latter populationmay transition between open,
bound receptors (O1 and O2) and desensitized, receptors (D). There
is also an open, unbound state (O0). At low ambient [GABA], the
lowest concentration of zolpidem (10 nM) has little effect on Koff
and the probability of transition to O1 and O2 is low. However, the
O0 state is stabilized by effects of benzodiazepine binding on
channel gating properties, which dominate over subtle effects on
Koff (Bianchi, 2010), and this leads to increased charge transfer
expressed macroscopically as enhancement of the tonic, unbound
GABAAR conductance (Wlodarczyk et al., 2013). At higher concen-
trations of zolpidem (30e1000 nM), zolpidem begins to depress
Koff, causing an apparent increase in afﬁnity of the GABAAR for GABA
and shifting the equilibrium toward an increase in Cb. The proba-
bility of moving from B into the O states at low ambient [GABA]
remains low, as most receptors will be singly bound, and conse-
quently the desensitized state, D, remains the highest afﬁnity
bound state. This leads to a shift in the equilibrium towards D, and
macroscopic desensitization in the absence of signiﬁcant increased
charge transfer. Hence, at 10 nM, zolpidem acts to stabilize an open,
unbound GABAAR through effects on gating leading to augmented
Itonic, and at 30e1000 nM, effects on afﬁnity dominate and desen-
sitization leads to a decreased macroscopic Itonic. When [GABA] is
raised artiﬁcially to 1000 nM most GABAAR are dual-bound, and
hence effects on afﬁnity dominate at all concentrations of zolpi-
dem, because the population of receptors in Cb is large. Here, the
equilibrium allows for transitions from B towards O and D, leading
to augmented macroscopic currents and/or slow desensitization.
This model is further supported by the effects of ﬂumazenil,
application of which reveals a persistent GABA current even in the
absence of zolpidem, suggesting that an endogenous
benzodiazepine-mediated stabilization of the O0 state exists in
neocortical slices in vitro (Christian et al., 2013). Furthermore, when
the proposed O0 state is maximally augmented through prolonged
incubation in 10 nM zolpidem at low ambient [GABA], the popu-
lation of receptors sequestered into this state would be predicted to
depress the rate and extent of maximal desensitization, since a
smaller receptor population would be available to participate due
to sequestration of receptors into the O0 state. This is observed
experimentally upon challenge of pre-incubated slices with 1 mM
GABA (Fig. 11). This sequestration of receptors into a kinetically
slow state presumably underlies the lack of effect of higher con-
centrations of zolpidem when applied subsequent to 10 nM zolpi-
dem. By contrast, pre-incubation of slices with higher
concentrations of zolpidem affects Koff, depressing the population
of receptors in U, dominating subtle gating effects, and effectively
depleting the pool of receptors in O0. This pushes the equilibrium
towards a high proportion of receptors in the B/O state, leading to
return of maximal rates and extent of desensitization when GABA
concentration is raised to mM levels.
4.3 Functional signiﬁcance
The differential concentration-dependent effects of zolpidem on
phasic and tonic inhibition in FS cells and consequent modulatory
effects on oscillatory activity highlight the complex interplay
E.J. Prokic et al. / Neuropharmacology 95 (2015) 192e205204between these two inhibitory mechanisms. Indeed, the constitu-
tively active Itonic, activated on FS cells by high afﬁnity receptors
may be a fundamental requirement for normal physiological
functioning. It may act as a ‘gatekeeper’, having the ability to sculpt
oscillatory power over a slower timescale than compared to phasic
inhibition by thresholding the level of FS cell activity (Pavlov et al.,
2009) and/or GABA before there is FS cell recruitment to an oscil-
lation. Recent reports of ‘endozepine’ activity in the thalamus
(Christian et al., 2013) conﬁrm the importance of the benzodiaze-
pine site in control of GABAA receptor function. Our data highlight
how subtle alterations in both GABA and benzodiazepine site
activation may confer radically different desensitization kinetics
onto GABAA receptors, and how this may alter network activity. The
origin of the GABA that activates receptors on FS cells is presumably
input from other GABA neurons. Such disinhibitory interneuronal
networks are currently a topic of great interest in understanding
cortical circuit function (Lee et al., 2013; Pi et al., 2013 see also
Klausberger et al., 2005).
The oscillations we have reported here are high beta/low
gamma. Others have shown that oscillations in vitro depend line-
arly on temperature (Dickinson et al., 2003) and it is not possible to
state with conﬁdence that they relate to pathological beta activity
as seen in Parkinson's, or indeed in vivo gamma activity as seen in
healthy brain in vivo. However, our previous clinical studies in M1
have shown that pathological slow wave and beta frequency os-
cillations can be suppressed by low-dose zolpidem (Hall et al., 2010,
2014), effects which correlate with improved cognitive and motor
function. It seems plausible that the effects of low-dose zolpidem
on FS interneurons and the modulation of tonic inhibition may
provide the mechanism underlying these clinical observations.
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